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Cyclophosphamide, methotrexate and ﬂuorouracil adjuvant combination chemotherapy for breast cancer is currently used for
the duration of six monthly courses. We performed a joint analysis of two studies on the duration of adjuvant
cyclophosphamide, methotrexate and ﬂuorouracil in patients with node-positive breast cancer to investigate whether three
courses of cyclophosphamide, methotrexate and ﬂuorouracil might sufﬁce. The International Breast Cancer Study Group Trial
VI randomly assigned 735 pre- and perimenopausal patients to receive ‘classical’ cyclophosphamide, methotrexate and
ﬂuorouracil for three consecutive cycles, or the same chemotherapy for six consecutive cycles. The German Breast Cancer
Study Group randomised 289 patients to receive either three or six cycles of i.v. cyclophosphamide, methotrexate and
ﬂuorouracil day 1, 8. Treatment effects were estimated using Cox regression analysis stratiﬁed by clinical trial without further
adjustment for covariates. The 5-year disease-free survival per cents (+s.e.) were 54+2% for three cycles and 55+2% for six
cycles (n=1024; risk ratio (risk ratio: CMF63/CMF66), 1.00; 95% conﬁdence interval, 0.85 to 1.18; P=0.99). Use of three
rather than six cycles was demonstrated to be adequate in both studies for patients at least 40-years-old with oestrogen-
receptor-positive tumours (n=594; risk ratio, 0.86; 95% conﬁdence interval, 0.68 to 1.08; P=0.19). In fact, results slightly
favoured three cycles over six for this subgroup, and the 95% conﬁdence interval excluded an adverse effect of more than 2%
with respect to absolute 5-year survival. In contrast, three cycles appeared to be possibly inferior to six cycles for women less
than 40-years-old (n=190; risk ratio, 1.25; 95% conﬁdence interval, 0.87 to 1.80; P=0.22) and for women with oestrogen-
receptor-negative tumours (n=302; risk ratio, 1.15; 95% conﬁdence interval, 0.85 to 1.57; P=0.37). Thus, three initial cycles of
adjuvant cyclophosphamide, methotrexate and ﬂuorouracil chemotherapy were as effective as six cycles for older patients (40-
years-old) with oestrogen-receptor-positive tumours, while six cycles of adjuvant cyclophosphamide, methotrexate and
ﬂuorouracil might still be required for other cohorts. Because endocrine therapy with tamoxifen and GnRH analogues is now
available for younger women with oestrogen-receptor-positive tumours, the need for six cycles of cyclophosphamide,
methotrexate and ﬂuorouracil is unclear and requires further investigation.
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The question of duration of adjuvant chemotherapy for breast
cancer has been directly addressed in several trials. Most of these
were small and, therefore, unsuitable for detecting differences of
modest magnitude (Bonadonna et al, 1987; Levine et al, 1990; Senn
and Jungi, 1984; Falkson et al, 1989; Henderson et al, 1986). A
meta-analysis of six such trials showed that a shorter treatment
duration (6 months) was as effective as a longer duration therapy
(12–24 months) (Early Breast Cancer Trialists’ Collaborative
Group, 1998a). The International Breast Cancer Study Group
(IBCSG) Trial V investigated the role of a single cycle of cyclopho-
sphamide, methotrexate, and 5-ﬂuorouracil (CMF) immediately
after the operation as compared with six or seven cycles of the
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www.bjcancer.comsame treatment for patients with node-positive disease (Ludwig
Breast Cancer Study Group, 1988). Although a single cycle of peri-
operative chemotherapy improved outcome compared with no
adjuvant chemotherapy in node negative disease (Ludwig Breast
Cancer Study Group, 1989), such treatment was found to be less
effective than a longer duration CMF in node positive disease
(Ludwig Breast Cancer Study Group, 1988). Without considering
subgroups, these results suggest that the optimal duration of adju-
vant CMF therapy for breast cancer is more than one but not more
than six 28-day cycles. The duration of a typical anthracycline-
containing regimen tested in several adjuvant trials is 3 months
(administered once every 3 weeks for four courses). This regimen
yielded similar disease-free and overall survival results compared
with six courses of CMF (Fisher et al, 1990, 2000).
Recently, the German Breast Cancer Study Group (GBSG)
reported the 10-year follow-up results of a randomised trial in
481 node-positive patients comparing three versus six cycles of
day 1 and 8 i.v. CMF (modiﬁed Bonadonna regimen) with or
without tamoxifen (Sauerbrei et al, 2000). No difference in overall
survival or event-free survival between the two durations of CMF
was found. The International Breast Cancer Study Group (IBCSG)
Trial VI compared three versus six cycles of initial ‘classical’ CMF
(oral cyclophosphamide) with or without three additional single
cycles of ‘reintroduction’ CMF for 1554 premenopausal women
with node-positive breast cancer. At 5 years’ median follow-up,
the IBCSG previously reported that three cycles of adjuvant
CMF chemotherapy yielded a shorter disease-free survival
compared with longer duration treatment, based on the entire trial
population (International Breast Cancer Study Group, 1996).
However, the increased risk of relapse with CMF63 was marked
for women aged less than 40 years and for patients with ER-nega-
tive tumours (International Breast Cancer Study Group, 1996);
patients older than 40 years had similar disease free survival times.
Furthermore, the patients assigned to three cycles showed more
rapid adjustment in self-reported quality of life (Hu ¨rny et al,
1996) and had signiﬁcantly less objective and subjective toxicity
than those assigned longer duration of therapy (International
Breast Cancer Study Group, 1996). To further clarify the role of
duration of adjuvant chemotherapy, we report a joint analysis
using individual data based on the recently published results of
the GBSG trial and updated results of IBCSG Trial VI with a
median follow up of 7.9 years. Both studies included two addi-
tional arms (two by two designs) that are not the subject of this
report.
PATIENTS AND METHODS
Description of trials
From July 1986 to April 1993, 1554 pre- and perimenopausal
breast cancer patients with node-positive disease were randomised
in IBCSG Trial VI in a two by two factorial design to receive the
following: (A) cyclophosphamide, methotrexate, and ﬂuorouracil
for six consecutive cycles on months 1 to 6 (CMF66); (B)
CMF66 plus three single cycles of reintroduction CMF given on
months 9, 12 and 15; (C) CMF for three consecutive cycles on
months 1 to 3 (CMF63); or (D) CMF63 plus three single cycles
of reintroduction CMF given on months 6, 9 and 12. The rando-
mization was stratiﬁed according to participating institution, type
of surgery (mastectomy vs breast-conserving procedure with breast
irradiation), and oestrogen receptor (ER) status (negative vs posi-
tive). The median follow-up was 7.8 years for disease free
survival and 7.9 years for overall survival. The protocol required
that the adjuvant chemotherapy begin within 6 weeks of surgery
and consist of CMF (cyclophosphamide 100 mg m
72 orally days
1-14, methotrexate 40 mg m
72 i.v. days 1 and 8, 5-ﬂuorouracil
600 mg m
72 i.v. days 1 and 8, repeated every 28 days). Oestrogen
receptor concentrations in the primary tumours were determined
by standard methods and concentrations 510 fmol mg
71 of
cytosol protein were considered positive; lower values negative.
Surgery of the primary tumour was either a total mastectomy with
axillary clearance, or a lesser procedure (quadrantectomy or
lumpectomy) with axillary lymph node dissection. For women trea-
ted with breast conserving surgery, radiotherapy was mandatory
and had to be postponed until the end of the initial phase of
chemotherapy (3 or 6 cycles).
From 1984 to 1989, 481 breast cancer patients were randomised
in the GBSG Trial in a two by two factorial design to receive either
three or six cycles of CMF and to receive two years of hormonal
therapy with tamoxifen or no hormonal therapy. The trial design
was the following: (A) CMF63; (B) CMF63+tamoxifen; (C)
CMF66; and (D) CMF66+tamoxifen. At the beginning of the
study, both pre- and postmenopausal patients were randomised
to all four arms of the study. However, starting in December
1986, premenopausal patients were only randomised to treatment
arms A and C. Chemotherapy was administered according to the
modiﬁed Bonadonna CMF regimen, which consisted of
500 mg m
72 cyclophosphamide, 40 mg m
72 methotrexate, and
600 mg m
72 ﬂuorouracil administered intravenously on days 1
and 8 of a 4-week treatment period. Chemotherapy started within
36 h after surgery. Hormonal treatment consisted of a daily dose of
3610 mg tamoxifen orally over 2 years, starting after the third
cycle of CMF. The median follow-up was 9.1 years for disease free
survival and 10.0 years for overall survival.
Statistical methods
A joint analysis of the two studies was performed to compare the
effectiveness of CMF63 and CMF66. Only data in arms A and C
from both studies were used in the analysis (CMF63 only and
CMF66 only treatment arms: Seven hundred and thirty-ﬁve
patients from the IBCSG trial and 289 patients from the GBSG
trial). Patient characteristics according to randomised treatment
are presented for each of the trials in Table 1. Disease-free survival
(DFS) was deﬁned as the time from surgery to relapse, second
malignancy, or death without relapse, whichever occurred ﬁrst.
Overall survival (OS) was deﬁned as the time from surgery to
death from any cause. Five-year DFS rates were calculated for each
treatment group by trial, as well as by age group (540, 540), by
ER status (negative, positive), and, for the IBCSG trial only, by
both age group and ER status. Risk ratios (RR) with pointwise
conﬁdence intervals for DFS comparing CMF63 to CMF66 were
calculated based on Cox models stratiﬁed by clinical trial without
inclusion of covariates (Cox, 1972). An RR greater than one
demonstrated that the risk of disease relapse for patients treated
with CMF63 was higher than for patients treated with CMF66.
Chi-square Wald statistics for the null hypothesis that the RR
equals one were calculated. Two-sided P-values less than 0.05 from
this test were considered signiﬁcant. Nine cases in the GBSG trial
did not have ER values, so they are not included in the DFS risk
ratios by ER status.
A graph of 95% conﬁdence intervals (CI) for the RR overall and
by age and ER status is presented in Figure 1. The size of the boxes
on the ﬁgure represents the amount of information available from
each subset (the larger the box, the more information provided).
Speciﬁcally, the box size is inversely proportional to the standard
error of the estimate of the natural log of the RR. Kaplan–Meier
curves of DFS for the two trials by treatment arm and also by
age group were generated (Kaplan and Meier, 1958). Kaplan–
Meier curves of OS by cooperative group and treatment arm were
created.
To describe the relationship between age and the magnitude of
treatment difference we used subpopulation treatment effect
pattern plots (STEPPs). This statistical method provides estimates
of the hazards ratios computed by the Cox model ﬁtted on over-
lapping subpopulations of patients, where the subpopulations are
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and Gelber, 2000). A second implementation of STEPP describes
the 5-year DFS estimated for each treatment group within each
of the overlapping subpopulations (Bonetti and Gelber, 2001).
Differences between the two CMF 3 vs 6 trials
The administration of CMF regimens differed between the trials.
Patients in the GBSG trial received i.v. CMF (modiﬁed Bonadonna
regimen), while oral cyclophosphamide and i.v. methotrexate and
ﬂuorouracil were given to patients in the IBCSG trial.
Patients in the GBSG study were randomised in most cases
following three cycles of CMF to avoid including early drop-outs
in the data analysis. Patients in the IBCSG study were rando-
mised prior to the ﬁrst cycle of CMF. To maintain consistency
between the two trials, surgery date was used as a common
starting date for calculation of time to event endpoints (age,
DFS, and OS). In the IBCSG study, follow-up information for
DFS and for OS were obtained from study forms submitted to
the data management center. In the GBSG study, DFS and OS
were based on clinic data; however, for some patients or clinics,
contacts were lost after some time. In these cases, information
about survival status was requested from the corresponding
registration ofﬁce. This additional information was used for OS
only.
In the published report on the GBSG study, patients with ER
values of 20 fmol mg
71 or greater were considered ER-positive.
ER values of 10 fmol mg
71 or greater were ER-positive in the
IBCSG study. The joint analysis considered ER values of
10 fmol mg
71 or greater to be ER-positive.
Timing of scheduled follow-up visits differed between the two
trials. In the IBCSG trial, the patients were seen every 3 months
for the ﬁrst 2 years, every 6 months for the next 3 years, and then
annually thereafter. Patients were scheduled to be seen more
frequently in the GBSG trial. They were seen every 3 months for
the ﬁrst 2 years after the operation, every 4 months for the follow-
ing 3 years, every 6 months for the following 2 years, and then
annually thereafter. Median follow-up was 7.8 years for disease free
survival in the IBCSG trial and 9.1 years in the GBSG trial. Of the
735 IBCSG patients, 381 had an event and of the 289 GBSG
patients, 170 had an event. Median overall follow-up for the IBCSG
trial was 7.9 years and 10.0 years for the GBSG trial. 254 of the 735
IBCSG patients died, and 143 of the 289 GBSG patients died thus
far.
As shown in Table 1, 51% of patients in the GBSG trial were at
least 50 years of age, while only 18% of patients in the IBCSG trial
were 50 or older. The majority of patients in both the GBSG and
IBCSG trials had ER-positive tumours (69 and 70%, respectively).
Most patients in both trials had between one and three positive
nodes (59 and 65%, respectively). A higher percentage of patients
in the GBSG trial had tumours larger than two centimeters, 71%
compared with 55% in the IBCSG trial. All of the GBSG patients
and 71% of the IBCSG patients had mastectomies.
RESULTS
Across all patients from both trials, DFS RRs of CMF63v
CMF66 revealed no difference between treatment groups (Figure
1, top). The RR for the 1024 patients was 1.00, with a DFS Cox
model P-value of 0.99 indicating no DFS difference between the
two treatments. Graphically, Figure 2A shows the similar
Kaplan–Meier DFS curves for the two treatments within each of
the individual trials. The 5-year DFS per cents+s.e. across both
trials were 54+2% for three cycles and 55%+2% for six cycles
(absolute difference [95% CI], 71% [77% to +6%]). The RR
of OS for the 1024 patients was 1.10 with 95% CI 0.90 to 1.34
(P=0.35). Figure 2B shows Kaplan–Meier curves for OS. The
ﬁve-year OS per cents+s.e. across both trials were 74+2% for
three cycles and 76+2% for six cycles (absolute difference [95%
CI], 71% [77% to +4%]).
For patients who were less than 40 years old (regardless of ER
status), results suggested an increased risk of relapse for patients on
CMF63 versus CMF66. Across both trials, for patients younger
than 40 years of age the RR was 1.25 with 95% CI 0.87 to 1.80
(P=0.22; Figure 1). For these patients, the 5-year DFS was 41+5%
for CMF63 compared with 48+5% for CMF66 (Figure 3A).
Five-year OS was 66+5% for CMF63 compared with 70+5% for
CMF66 for patients younger than 40 years of age. The STEPP
analyses for the IBCSG trial (Figures 4A,C) graphically showed that
differences in treatment effect are likely to occur across the conti-
nuum of age, with CMF63 compromising DFS for patients 540
compared with CMF66. Both the Cox model implementation of
STEPP (Figure 4A) and the plot showing 5-yearDFS per cents (Figure
4C) illustrate improved outcome for younger patients in the CMF66
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Table 1 Patient characteristics according to randomised treatment
IBCSG GBSG
CMF63 CMF66 Both CMF63C M F 66 Both
Total Patients 360 375 735 145 144 289
Factor % % % % % %
Age
540 23 19 21 14 12 13
4 0 – 4 9 6 16 1 6 1 3 73 6 3 6
50 or older 16 20 18 50 52 51
ER status
Negative 30 30 30 30 26 28
Positive 70 70 70 66 72 69
Unknown 0 0 0 4 2 3
Nodes positive
Between 1 and 3 65 65 65 59 60 59
Four or more 35 35 35 39 40 40
Unknown 0 0 0 2 0 1
Tumour size
42 c m 4 34 2 4 3 2 82 9 2 9
42 c m 5 55 5 5 5 7 07 1 7 1
Unknown 2 3 2 1 0 0
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(11), 1705–1714group. Because there were so few patients under 40 in the GBSG trial,
this effect could not be investigated in Figures 4B and 4D.
The results for all patients with ER-negative tumours (n=302)
also showed a possible increased risk for the CMF63 group
(Figure 1, RR=1.15; 95% CI=0.85 to 1.57; P-value=0.37). Five-year
DFS Kaplan–Meier estimates for this patient subpopulation were
48+4% for three cycles compared with 54+4% for six cycles of
CMF. Five-year OS Kaplan–Meier estimates were 60+4% for
three cycles compared with 71+4% for six cycles of CMF. Both
the IBCSG and GBSG studies showed that CMF63 may not be
sufﬁcient for ER-negative patients (RR 1.18 and 1.08, respectively,
Figure 1), although the results were not statistically signiﬁcant.
The increased risk of relapse in the CMF63 group for patients
under 40-years-old was observed both for patients with ER-positive
and for those with ER-negative tumours. The RR for patients less
than 40-years-old with ER-negative tumours was 1.57 and for
patients less than 40 with ER-positive tumours was 1.54. Neither
RR was statistically signiﬁcantly different from one. Because there
were so few GBSG patients who were younger than 40, only IBCSG
data were used for these calculations (Figure 5).
For patients at least 40-years-old with ER-positive tumours, use
of three cycles did not increase the risk of relapse compared with
six cycles of CMF (Figure 5, n=594, RR=0.86, 95% CI=0.68 to
1.08, P-value=0.19). This result was consistent for each of the trials.
The IBCSG trial had an RR of 0.85 with 95% CI 0.65 to 1.13 and
the GBSG trial had an RR of 0.87 with 95% CI 0.59 to 1.28. Across
both trials, the 5-year DFS+SE was 61+3% for three cycles of
CMF and 57+3% for six cycles of CMF (absolute difference
[95% CI], +4% [74 to +12%]). Five-year OS+SE was 83+2%
for three cycles of CMF and 79+2% for six cycles of CMF for
patients at least 40 years old with ER-positive tumours (absolute
difference [95% CI], +4% [72 to +11%]).
In general, formal tests for interaction between the duration of
CMF and either age or ER status alone were not statistically signif-
icant (Figure 1; P=0.17 for age and P=0.33 for ER). Among
patients with ER-positive tumours, however, the longer duration
treatment provided beneﬁt for younger women but not for older
women (Figure 5; P-value for interaction=0.03).
DISCUSSION
There is high quality evidence that adjuvant cytotoxic chemother-
apy delays relapse and prolongs survival for patients with early
breast cancer (Early Breast Cancer Trialists’ Collaborative Group,
1998a). As in other areas of medicine, once primary efﬁcacy has
been demonstrated research efforts move to evaluate secondary
questions addressing optimization of the balance between the bene-
ﬁts of such treatment and its subjective and objective costs. One
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Disease-free survival risk ratios
Group        CMFx3       CMFx6         RR         for RR      P-value
No. of events/
No. of patients 95% CI 95% CI
  (CMFx3:CMFx6)
    IBCSG       186/360     195/375       1.04      (0.85,1.27)    0.69
    GBSG          84/145       86/144       0.92     (0.68,1.24)    0.57
    Both           270/505     281/519       1.00     (0.85,1.18)    0.99
<40
    IBCSG         58/83           38/70       1.54     (1.02,232)     0.04
    GBSG          10/20           15/17       0.57     (0.26,128)     0.17
    Both             68/103         53/87       1.25      (0.87,1.80)    0.22
40+
    IBCSG       128/277     157/305       0.90      (0.71,1.14)    0.38
    GBSG          74/125       71/127       1.00     (0.72,1.38)    0.99
    Both           202/402     228/432       0.93     (0.77,1.13)    0.47
ER–
    IBCSG         59/109       56/111       1.18     (0.82,1.70)    0.38
    GBSG          27/44         21/38         1.08      (0.61,1.93)    0.78
    Both             86/153        77/149        1.15      (0.85,1.57)    0.37
ER+
    IBCSG       127/251     139/264       0.99     (0.78,1.26)    0.92
    GBSG          56/95         63/103       0.88      (0.61,1.26)    0.47
    Both           183/346     202/367       0.95      (0.78,1.16)    0.63
0.25           0.5            1.0            2.0             4.0
CMFx3 better CMFx6 better
ALL
Figure 1 Risk ratios comparing three cycles vs six cycles of CMF overall and according to age (540, 540) and ER status (negative, positive).
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chemotherapy. In premenopausal women, cytotoxic therapy is
thought to exert its effects both by direct tumour cell kill and by
an endocrine mechanism secondary to suppression of ovarian func-
tion (Pagani et al, 1998). The extent to which chemotherapy may
exert such an endocrine effect will depend on the type of
chemotherapy, the age of the patient (known to inﬂuence the
probability of chemotherapy-induced amenorrhea; Pagani et al,
1998; Goldhirsch et al, 1990), and the hormone receptor expression
of the tumour (endocrine therapy will be more important in recep-
tor-positive disease; Scottish Cancer Trials Breast Group and ICRF
Breast Unit, 1993). Effective alternative forms of endocrine therapy
such as tamoxifen (Early Breast Cancer Trialists’ Collaborative
Group, 1998b), ovarian ablation, and medical suppression of ovar-
ian function are available, so the optimal duration of cytotoxic
therapy may also depend on whether or not such treatments are
used. Endocrine non-responsive disease is controlled only by the
direct cytotoxic effects of chemotherapy and the beneﬁt of longer
duration chemotherapy might best be studied in this setting in
the absence of endocrine therapies.
Several trials examine regimens which differ in duration of ther-
apy but also in the drugs given. In these trials the effects of
duration and choice of drug are inextricably confounded. They
reach varying conclusions about treatment duration. Thus, one of
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DFS by group and treatment arm A
100
80
60
40
20
0
IBCSG CMFx6
IBCSG CMFx3
GBSG CMFx6
GBSG CMFx3
5-year DFS % (SE)
CMFx3    CMFx6
IBCSG      55(3)      58(3)
GBSG       51(4)      47(4)
Overall      54(2)      55(2)
0123 456789 1 0  
No. at risk Years
IBCSG CMFx3  360        328          270        236          214        187         148         117          82           53           27
IBCSG CMFx6  375        350          303        261          236        204         164         127          87           47           26
 GBSG CMFx3  145        128          107          85            73          65           58           52          44           32           22
 GBSG CMFx6  144        127          101          83            69          58           50           40          29           25          14
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OS by group and treatment arm
No. at risk Years
IBCSG CMFx3  360        353          340        317          292        258         205         165        117           73           34
IBCSG CMFx6  375        374          352        329          309        274         230         181        120           68           35
 GBSG CMFx3  145        141          127        117          109          97           87           81          73           56           33
 GBSG CMFx6  144        142          127        118          107        102           95           86          75           52           31
B
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IBCSG CMFx6
IBCSG CMFx3
GBSG CMFx6
GBSG CMFx3
5-year OS % (SE)
CMFx3    CMFx6
IBCSG      76(2)      77(2)
 GBSG       70(4)      72(4)
Overall      74(2)      76(2)
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Figure 2 Kaplan–Meier plots of disease-free survival according to cooperative group and treatment (A) and Kaplan–Meier plots of overall survival ac-
cording to cooperative group and treatment (B).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(11), 1705–1714the most frequently used anthracycline-containing adjuvant therapy
programs, four cycles of intravenous doxorubicin (Adriamycin
1)
and cyclophosphamide (AC) combination given once every 3
weeks, is administered entirely within 63 days. In a direct compar-
ison, six courses of classical CMF (154 days) and four courses of
AC yielded similar results despite the different durations (Fisher
et al, 1990, 2000). Likewise a short but complex 16-week regimen
(including a continuous administration of cytotoxics during the
entire period of treatment) yielded results marginally superior to
those seen with six courses of cyclophosphamide, doxorubicin
and 5-ﬂuorouracil (CAF) (Fetting et al, 1998). On the other hand,
the US Intergroup trial of the addition of 4 cycles of paclitaxel
(Taxol
1) following four cycles of AC demonstrated a small but
signiﬁcant improvement in disease-free and overall survival using
the longer, different regimen (Henderson et al, 1998). This
improvement was seen almost exclusively among patients with
ER-negative tumours who did not receive tamoxifen.
Evidence already available deﬁnes broad limits within which the
optimal duration of adjuvant CMF therapy may be expected to be
found. The EBCTCG overview found no advantage in extending
therapy beyond about 6 months (Early Breast Cancer Trialists’ Colla-
borative Group, 1998a). International Breast Cancer Study Group
Trial V demonstrated that a single peri-operative cycle of CMF
was less effective than a course of six or seven cycles of CMF (Ludwig
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DFS by group and treatment arm A
100
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IBCSG CMFx6
IBCSG CMFx3
GBSG CMFx6
GBSG CMFx3
5-year DFS % (SE)
 CMFx3   CMFx6
IBCSG      39(  5)    53(  6)
GBSG       50(11)      29(11)
Overall      41(  5)    48(  5) 
No. at risk Years
IBCSG CMFx3   83          74           49          43           36           30           23           16           13           11            7
IBCSG CMFx6   70          61           54          45           39           36           32           27           21           13            7
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Figure 3 Kaplan–Meier plots of disease-free survival according to cooperative group and treatment for patients less than 40 years of age (A) and for
patients 40 years of age or older (B).
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some therapeutic beneﬁt (Ludwig Breast Cancer Study Group,
1989). There is little evidence directly comparing treatment regimens
of between more than one and 6 months duration.
There are additional reasons to investigate the question of treat-
ment duration. Subjectively, a course of three cycles of CMF was
better tolerated, and associated with more rapid improvement in
quality of life than 6 cycles (Hu ¨rny et al, 1996). Less toxicity was
observed with three cycles of CMF in the GBSG study (Schumacher
et al, 1994). Three cycles of CMF chemotherapy was also shown to
be effective in addition to tamoxifen therapy in postmenopausal
patients, with minimal adverse effect on quality of life (Casti-
glione-Gertsch et al, 2000). Finally, shorter duration treatments
are less costly than longer durations of the same agents.
In this joint analysis we investigated the issue of duration of
CMF chemotherapy by choosing two trials, conducted by the
IBCSG (International Breast Cancer Study Group, 1996) and the
GBSG (Sauerbrei et al, 2000) that used the same three agents in
similar schedules and common study questions, though with differ-
ent routes of cyclophosphamide administration. Both studies also
addressed other questions. In this analysis we avoided these poten-
tial confounding treatment factors, which included the use of
tamoxifen (GBSG) and additional cycles of chemotherapy (IBCSG),
by selecting only the data from patients randomised to receive
three or six cycles of CMF in each study.
The two studies jointly reviewed here demonstrate that for the
overall population and especially for older patients (40 years and
above) with hormone-receptor positive tumours three cycles of
CMF chemotherapy is nearly identical to six cycles, even in the
absence of speciﬁc additional endocrine therapy. This is consistent
with the EBCTCG overview (Early Breast Cancer Trialists’ Colla-
borative Group, 1998a), which found a real but relatively small
beneﬁt for any chemotherapy in older patients with ER-positive
tumours. Such patients are now routinely treated with tamoxifen
or ovarian ablation in addition to chemotherapy, presumably
further reducing the need for more prolonged cytotoxic therapy.
The evidence to support the shorter duration of chemotherapy
compared with the longer standard duration is, however, unreliable
for younger patients and for those with ER-negative disease, and
the longer duration treatment might be beneﬁcial for these cohorts.
Since the current analysis was performed, Maass (2000) have
presented preliminary data from a further German trial (GABG
III) comparing three versus six cycles of adjuvant CMF and
conﬁrming no overall difference between the treatment groups.
Based on 789 patients with one to nine axillary lymph nodes
involved at a median follow-up of 35 months, no difference in
disease-free (P=0.34) or overall survival (P=0.17) was found (three
versus six cycles: percent relapsing, 31.3 vs 30.4%; per cent dead,
14.8 vs 12.8%). Data for subgroups according to age and steroid
hormone receptor status of the primary tumour were not
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Figure 4 Subpopulation Treatment Effect Pattern Plots (STEPPs) according to age for the IBCSG trial (A and C) and for the GBSG trial (B and D).
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any subgroup. As far as we know, the GBSG, IBCSG and GABG
trials are the only randomised studies evaluating three versus six
cycles of CMF, and all demonstrated no overall difference between
treatment arms.
We previously published data from IBCSG Trial VI according to
amenorrhea suggesting that the endocrine effects of chemotherapy
alone are insufﬁcient for the younger age group with ER/PgR posi-
tive tumours (Pagani et al, 1998). In this study women who
experienced amenorrhea had a signiﬁcantly better DFS than those
who did not. DFS differences between amenorrhea categories were
larger for patients with ER/PgR positive tumours. The role of
chemotherapy induced amenorrhea appeared evident also when
outcome was analyzed in a population of 314 very young (535
years) premenopausal patients enrolled in trials of adjuvant
chemotherapy (Aebi et al, 2000). The worst prognosis was observed
for younger patients with ER-positive tumours who did not achieve
amenorrhea. As indicated by the STEPP plots for the current joint
analysis, differences in treatment effect are likely to occur across
the continuum of age. Thus, clinical decisions concerning the use
of three rather than six courses of CMF might be based on assess-
ment of likelihood for chemotherapy-induced amenorhea rather
than on a ﬁxed age cut-point.
The results of subgroup analyses should be treated with caution,
especially because some of the subgroups had small sample sizes.
However, there is some biological rationale for expecting beneﬁt
of longer duration therapy in the subpopulation of patients with
ER-negative tumours. Such tumours have a more rapid cell prolif-
eration and are associated with a higher risk of relapse despite
adjuvant chemotherapy. Prolonged duration of chemotherapy
may, therefore, be particularly relevant to inhibit the growth of
tumours that are not susceptible to the effects of endocrine thera-
pies due to lack of ER.
As the risk of relapse increases (higher number of positive
nodes) the likelihood that an ER-positive phenotype has a propor-
tion of chemotherapy responsive cells also increases. Therefore,
although the overall cohort of older patients with ER-positive
tumours was safely treated with the shorter duration of chemother-
apy, it is possible that the longer duration of chemotherapy
provides a modest beneﬁt for patients with ER-positive tumours
at high risk of relapse especially in the absence of tamoxifen
(Henderson et al, 1998; Goldhirsch et al, 2000).
Historically, patients were classiﬁed as having ER-negative
(510 fmol mg
71 cytosol protein or 510% of positive cells) and
ER-positive (510 fmol mg
71 cytosol protein or 510% of positive
cells) tumours to facilitate prediction of response to endocrine
therapies. However, there is recent evidence that tumours with less
than 10% of weakly positive cells still may experience tumour
response, compared with those who had no detectable ER staining
(Harvey et al, 1999). These data lead to the conclusion that dura-
tion of chemotherapy might be tested best in patients with ER-
absent tumours, where the cytotoxic rather than endocrine effects
of chemotherapy might be even larger. Although this is a small
subset compared with the entire breast cancer population, it might
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Disease-free survival risk ratios
Group        CMFx3       CMFx6         RR         for RR      P-value
No. of events/
No. of patients 95% CI
  (CMFx3:CMFx6)
    IBCSG           20/31         11/23       1.57      (0.75,3.29)    0.23
<40   ER+
    IBCSG           38/52          27/47       1.54     (0.94,253)     0.09
40+   ER–
    
    IBCSG           39/78         45/88       1.04      (0.68,1.60)    0.86
 
    GBSG            24/34         17/33       1.40     (0.75,2.63)    0.29
    Both             63/112        62/121      1.14      (0.81,1.63)    0.45
40+   ER+
    
    IBCSG         89/199     112/217       0.85     (0.65,1.13)    0.27    
    
    GBSG            49/87         52/91       0.87      (0.59,1.28)    0.48
    
    Both           138/286     164/308       0.86      (0.68,1.08)    0.19
0.25           0.5            1.0            2.0             4.0
CMFx3 better CMFx6 better
<40   ER–
95% CI
Figure 5 Risk ratios comparing three cycles vs six cycles of CMF according to subpopulations deﬁned by both age (540, 540) and ER status (negative,
positive). Because there were so few GBSG patients who were younger than 40, only IBCSG data were used for these calculations.
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tigations of adjuvant chemotherapy questions, especially in the
absence of confounding endocrine therapies.
We conclude that patients with potentially endocrine responsive
node-positive disease who are over 40 years of age can be
adequately treated with three rather than six cycles of CMF espe-
cially if it is followed by tamoxifen. The reduction in the
amount of chemotherapy would signiﬁcantly reduce subjective
and objective toxicity. It is difﬁcult to draw ﬁrm conclusions for
younger patients based on this analysis because there are so few
younger patients, particularly in the GBSG trial, and chemotherapy
was the only adjuvant treatment. Perhaps three cycles of CMF
would be sufﬁcient also for women aged under 40 with hormone
receptor positive, potentially endocrine responsive node-positive
disease if CMF were followed by effective endocrine therapy.
Indeed recent studies (Jakesz et al, 1999; Roche et al, 2000; Boccar-
do et al, 2000) show endocrine therapy alone with the combination
of GnRH analogue plus tamoxifen is equally effective or superior to
chemotherapy alone, clearly implying that the endocrine compo-
nent of any chemoendocrine therapy provides the dominant
effect for these patients.
For women of any age with tumours that do not express any
steroid hormone receptors (ER-absent) (a relatively small subgroup
of patients), the issue of adjuvant chemotherapy duration requires
further study, but our results do not suggest that adjuvant CMF
can safely be reduced to three cycles in these women.
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